The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
P53 status in primary tumor predicts efficacy of first-line abiraterone and enzalutamide in castration-resistant prostate cancer patients.
 
Benjamin Louis Maughan
No Relationships to Disclose
 
Liana Guedes
No Relationships to Disclose
 
Kenneth M. Boucher
No Relationships to Disclose
 
Gaurav Rajoria
Employment - Pathline Emerge
Research Funding - Pathline Emerge
 
Zach Liu
Employment - Pathline Emerge
Research Funding - Pathline Emerge
 
Szczepan Klimek
Employment - Pathline Emerge
Research Funding - Pathline Emerge
 
Roberto Zoino
Employment - Pathline Emerge
Research Funding - Pathline Emerge
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Tamara L. Lotan
No Relationships to Disclose